Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. Fecha: Martes 16 de abril
Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Authors:
Pavord ID1, Hanania NA2.
1 Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: ian.pavord@ndm.ox.ac.uk.2 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas.
Abstract:
There have been major advances in the assessment and management of severe asthma over the last 10 years. As a result, many patients with severe asthma have new, targeted biological treatment options. These biologic therapies are only effective in subgroups (phenotypes) of patients defined using clinical parameters and biomarkers. All biologic therapies approved at the moment target type 2 high or eosinophilic airway inflammation.
We use a case-based discussion approach to discuss biological treatment options for a patient presenting with severe eosinophilic asthma. There remains much debate on the choice of specific biologic in such a case. This issue is the focus of this article that presents a debate as to whether to use biologics targeting IL-5 or other biologics in this case.
DOI: 10.1016/j.jaip.2019.03.010
Comentarios
Publicar un comentario